COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2020

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

(1, 2) , (3, 4) , (1) , (4) , (1, 2)
1
2
3
4

Domains

Life Sciences [q-bio] Cancer Life Sciences [q-bio] Human health and pathology Pulmonology and respiratory tract Life Sciences [q-bio] Microbiology and Parasitology Virology Life Sciences [q-bio] Human health and pathology Emerging diseases
Fichier principal
Vignette du fichier
PIIS0959804920301933.pdf (1016.17 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Myriam Bodescot  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-02565846

Submitted on : Wednesday, May 6, 2020-4:54:59 PM

Last modification on : Monday, November 28, 2022-4:58:05 PM

Download

Dates and versions

inserm-02565846 , version 1 (06-05-2020)

Identifiers

Cite

Alessandro Leonetti, Francesco Facchinetti, Teresa Zielli, Elena Brianti, Marcello Tiseo. COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors. European Journal of Cancer, 2020, 132, pp.122-124. ⟨10.1016/j.ejca.2020.04.004⟩. ⟨inserm-02565846⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM FNCLCC IGR UNIV-PARIS-SACLAY GS-HEALTH-DRUG-SCIENCES
89 View
116 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More